TransMedics Group, Inc. (TMDX) Q2 2023 Earnings Call Transcript

TransMedics Group, Inc. (NASDAQ:TMDX) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET

Company Participants

Brian Johnston – Gilmartin Group

Waleed Hassanein – President and CEO

Stephen Gordon – CFO

Conference Call Participants

Bill Plovanic – Canaccord

Allen Gong – JPMorgan

Suraj Kalia – Oppenheimer

Ryan Daniels – William Blair

Josh Jennings – TD Cowen


Good afternoon, and welcome to TransMedics Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder, this call is being recorded for replay purposes.

I’d now like to turn the call over to Brian Johnston from the Gilmartin Group for a few introductory comments.

Brian Johnston

Thank you. Earlier today TransMedics released financial results for the quarter-ended June 30, 2023. A copy of the press release is available on the company’s website.

Before we begin, I would like to remind you that management will make statements during this call, including during the question-and-answer section that include forward-looking statements within the meaning of Federal Securities laws. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.

All forward-looking statements including without limitation, are examination of operating trends, the potential commercial opportunity for our products and our future financial expectations, which include expectations for growth in our organization and guidance and/or expectations for revenue, gross margins and operating expenses in 2023 are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results over events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements.

Additional information regarding these risks

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *